Literature DB >> 33562455

A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma.

Alessandro Comandone1,2, Antonella Boglione1,2, Tiziana Comandone2,3, Fausto Petrelli2,4.   

Abstract

Osteosarcomas (OSs) are a group of neoplasms originating from bone cells, usually presenting in three specific age groups: children, young adults, and the elderly. High-grade OS is an extremely malignant tumor mainly due to evolution into metastatic disease, usually in the lungs. Survival of these patients has improved since the 1980s thanks to close cooperation between oncologists, oncological surgeons and orthopedic surgeons. Unfortunately, no progress has been made in the last 30 years and new, more effective drugs are needed. This article reviews the biological and pharmacological basis of the treatment of OS. Models of clinical pharmacology of the active drugs, toxic effects and reasons for primary and secondary resistance to old and new drugs are discussed.

Entities:  

Keywords:  chemotherapy; osteosarcoma; pharmacology; resistance; target therapy

Mesh:

Year:  2021        PMID: 33562455      PMCID: PMC7915093          DOI: 10.3390/medicina57020141

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  43 in total

1.  Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy.

Authors:  Gaetano Bacci; Alessandra Longhi; Franca Fagioli; Antonio Briccoli; Michela Versari; Piero Picci
Journal:  Eur J Cancer       Date:  2005-11-17       Impact factor: 9.162

2.  Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Authors:  Gary K Schwartz; William D Tap; Li-Xuan Qin; Michael B Livingston; Samir D Undevia; Bartosz Chmielowski; Mark Agulnik; Scott M Schuetze; Damon R Reed; Scott H Okuno; Joseph A Ludwig; Vicki Keedy; Petra Rietschel; Andrew S Kraft; Douglas Adkins; Brian A Van Tine; Bruce Brockstein; Vincent Yim; Christiana Bitas; Abdul Abdullah; Cristina R Antonescu; Mercedes Condy; Mark A Dickson; Shyamprasad Deraje Vasudeva; Alan L Ho; L Austin Doyle; Helen X Chen; Robert G Maki
Journal:  Lancet Oncol       Date:  2013-03-08       Impact factor: 41.316

Review 3.  Karnofsky memorial lecture. Ode to methotrexate.

Authors:  J R Bertino
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

4.  Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.

Authors:  Stefano Ferrari; Sigbjorn Smeland; Mario Mercuri; Franco Bertoni; Alessandra Longhi; Pietro Ruggieri; Thor A Alvegard; Piero Picci; Rodolfo Capanna; Gabriella Bernini; Cristoph Müller; Amelia Tienghi; Thomas Wiebe; Alessandro Comandone; Tom Böhling; Adalberto Brach Del Prever; Otte Brosjö; Gaetano Bacci; Gunnar Saeter
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

5.  Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.

Authors:  Patrick Van Winkle; Anne Angiolillo; Mark Krailo; Ying-Kuen Cheung; Barry Anderson; Virginia Davenport; Gregory Reaman; Mitchell S Cairo
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167

6.  Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.

Authors:  Stefano Ferrari; Antonio Briccoli; Mario Mercuri; Franco Bertoni; Piero Picci; Amelia Tienghi; Adalberto Brach Del Prever; Franca Fagioli; Alessandro Comandone; Gaetano Bacci
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

7.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.

Authors:  G Grignani; E Palmerini; P Dileo; S D Asaftei; L D'Ambrosio; Y Pignochino; M Mercuri; P Picci; F Fagioli; P G Casali; S Ferrari; M Aglietta
Journal:  Ann Oncol       Date:  2011-04-28       Impact factor: 32.976

8.  Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

Authors:  Jaume Mora; Cheeu Ofelia Cruz; Andreu Parareda; Carmen de Torres
Journal:  J Pediatr Hematol Oncol       Date:  2009-10       Impact factor: 1.289

9.  Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model.

Authors:  Claudia Christowitz; Tanja Davis; Ashwin Isaacs; Gustav van Niekerk; Suzel Hattingh; Anna-Mart Engelbrecht
Journal:  BMC Cancer       Date:  2019-08-01       Impact factor: 4.430

10.  Single-Center Experience with Ifosfamide Monotherapy as Second-Line Treatment of Recurrent/Metastatic Osteosarcoma.

Authors:  Arie Jan Verschoor; Frank M Speetjens; P D Sander Dijkstra; Marta Fiocco; Michiel A J van de Sande; Judith V M G Bovée; Hans Gelderblom
Journal:  Oncologist       Date:  2019-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.